Abstract

MINNEAPOLIS (EGMN) - BRAF mutations may offer one answer to the growing need for biomarkers that can accurately predict the risk of thyroid cancer recurrence, said Dr. Stefan K.G. Grebe.Thyroid cancer, with its rising incidence and low mortality rate, will be the third most common diagnosis in living cancer patients in the next 5-10 years, behind breast and prostate cancers, according to Dr. Grebe. For a newly diagnosed thyroid cancer patient, the lifetime risk of dying from the disease in 10 years...